Effects of gamma-globulin on the cardiac sequelae of Kawasaki disease.
Our aim was to delineate the effect of various factors, such as sex, age, serum albumin levels, and the timing of gamma-globulin (GG) therapy, on cardiac sequelae of Kawasaki disease. The patients with Kawasaki disease who were reported at the 1995-1996 nationwide survey and received 2000 mg/kg at specified hospitals were selected as the subjects of the study. A total of 2221 patients actually received the basic dose. The relationships of the GG therapy with the cardiac sequelae, sex, age, timing of GG administration (the date of initiation and duration of the regimen following disease onset), and serum albumin levels were examined by using logistic regression analysis. The odds ratios for the cardiac sequelae in patients with Kawasaki disease were high in males (1.63), in those under the age of 1 year (1.54), and in those with a serum albumin level <3.2 g/dl (2.64). The odds ratio was low in those who received GG before day 8 of the illness (0.69) or in those for whom the administration period was for 2 days or less (0.67). To prevent cardiac sequelae of Kawasaki disease it is desirable that GG therapy be started as soon as possible and completed within 2 days.
Yanagawa
H
H
Department of Public Health, Jichi Medical School, 3311 Yakushiji, Minamikawachi-machi, Tochigi-ken 329-0498, Japan.
Tuohong
Z
Z
Oki
I
I
Nakamura
Y
Y
Yashiro
M
M
Ojima
T
T
Tanihara
S
S
D017677:Age Distribution; D002675:Child, Preschool; D015897:Comorbidity; D003625:Data Collection; D004305:Dose-Response Relationship, Drug; D005260:Female; D006331:Heart Diseases / Q000453:epidemiology* / Q000517:prevention & control*; D006801:Humans; D015994:Incidence; D007223:Infant; D007564:Japan / Q000453:epidemiology; D016015:Logistic Models; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D015999:Multivariate Analysis; D016017:Odds Ratio; D012307:Risk Factors; D017678:Sex Distribution; D015996:Survival Rate; D016896:Treatment Outcome; D005719:gamma-Globulins / Q000008:administration & dosage*
D005719:gamma-Globulins